Keyword: Torrent Pharmaceuticals
Novartis pivots Shanghai R&D from discovery to development. BeiGene nabs FDA nod for BTK inhibitor Brukinsa. FDA clears Shionogi's antibiotic Fetroja.
The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.
AZ and Daiichi's antibody-drug conjugate nabs FDA priority review; FDA shames Torrent for tainted heart drugs; Takeda sells emerging markets drugs.
An FDA warning letter lays out failures by a Torrent Pharmaceuticals plant that figures into the global recall of tainted high blood pressure meds.
Avanir pays $116 million in Neudexta kickback suits; China unveils results for a procurement scheme; Aurobindo founder faces insider trading fine.
Interruptions continue to wreak havoc on the global drug supply as drugmakers respond to the detection of impurities in some commonly used meds.
Takeda releases first post-Shire guidance; Indian generics makers are named in a price-fixing suit; Daiichi's quizartinib fails at FDA.
The FDA says Torrent finished product batches were out of spec 340 times in two years, but the company often approved them after retesting.
Teva has added 35 lots to a nationwide recall of losartan made with an active ingredient found to be tainted with a suspected carcinogen.
Lilly sells legacy antibiotics in China; Daiichi picks a bispecific antibody in Zymeworks deal; Torrent recalls more than 1 million losartan bottles.